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ABSTRACT 
Research in gene therapeutic strategies involving oligonucleotides (ONs) constitutes a 
growing field with several clinical products already approved and many more under intense 
investigation. The recent advances have mainly involved the Antisense ON platform, with the 
aim of modulating gene expression on the RNA level. In contrast, targeting DNA using anti-
gene ONs is a much less explored therapeutic option, but has been shown to be able to 
provide a potent alternative for the modulation of gene expression. Many genetic diseases 
originate in mutations in the genome, and by directly targeting these using anti-gene ONs 
could potentially have advantages over RNA based options, including lower dosage and 
reduced toxicity.  
In this thesis, several anti-gene therapeutic approaches involving ONs are presented, 
optimized and evaluated both in vitro and in cells. In Paper I, a novel approach for the 
generation of Zorro-LNA using click chemistry is developed, in order to join the two anti-
gene ONs involved in a 3´-5´- 5´-3´orientation.  This strategy replaces the use of reverse 
LNA phosphoroamidites and provides a screening platform suitable for optimizing new 
Zorro-LNA constructs. In paper II, single stranded ONs targeting the CAG-repeat region in 
the Huntingtin gene is used to down-regulate the mutant protein responsible for Huntington´s 
disease. The ONs are active in patient-derived fibroblasts and can efficiently reduce both 
mRNA and protein levels up to seven days following transfection and naked uptake delivery 
strategies. We also demonstrate, in different assays, that the mode of action is through ON 
binding to DNA, and not through RNA interactions.  
In paper III, we optimize different bisLNA anti-gene ON constructs for efficient DNA strand 
invasion using novel chemistries and intercalators. We demonstrate the selective binding 
through both Hoogsteen and Watson-Crick hydrogen bonding to supercoiled DNA in a 
physiological environment. In addition, the DNA binding is assessed in bacterial cells and 
detected using rolling circle amplification. Paper IV evaluates the specific delivery to cancer 
cells using aptamer-mediated uptake of LNA-containing ONs. The effect on the aptamer 
plasticity is investigated using chemical modifications, both in the cargo ON and in the 
aptamer itself, as well as the influence of the construct properties on cellular uptake in two 
different cell lines. Taken together, the results presented in this thesis aims at advancing the 
anti-gene based ON therapeutic strategies in terms of efficacy and specific delivery.  
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1 INTRODUCTION 
1.1 GENE THERAPY 
The use of gene therapy to restore dysfunctional genes in disease has come a long way since 
the first steps were taken some 50 years ago (1-4). 25 years ago the first clinical trials 
involving gene therapy were conducted (5), and even though they were unsuccessful they 
marked the beginning of a rapid development and expansion of the field in the last decades. 
Looking at the combined US and EU market today, five therapeutic products have been 
approved using genetic material to treat diseases (6, 7): Fomivirsen for cytamegalovirus 
retinitis in 1998 (US), Pegaptanib against age-related macular degeneration in 2004 (US), 
Apolipogene tipavovec for lipoprotein lipase deficiency in 2012 (EU), Mipomersen for 
familiar hypercholesterolemia in 2012 (US), Strimvelis for severe combined 
immunodeficiency due to adenosine deaminase deficiency in 2016 (EU) and recently 
Eteplirsen for Duchenne muscular dystrophy in 2016 (US). Given the technical progress 
seen in the last 10 years together with the detailed mapping of the human genome, no doubt 
the future holds great promise when it comes to treating genetic diseases using many of the 
possible gene therapeutic strategies. 
Mutations in protein coding or regulatory genes can give rise to proteins that either lack 
correct function, gained a new pathological function or exist in suboptimal quantities. These 
changes in normal protein physiology are in many cases associated with disease progression. 
Dominant diseases carry such mutations in the hererozygous state, i.e. when the mutation is 
present on one of the gene copies (allele). In families, dominant diseases affect the dominant 
parent carrier and the offspring inheriting the mutant allele. Recessive diseases need both 
alleles to be mutated for symptoms to appear. Affected offspring must have parents with one 
mutant allele each, which will be asymptomatic since they are only carriers for the trait. 
Depending on the molecular origin and pathophysiological mechanism underlying a certain 
genetic disease, multiple targeting options exist along the pathway of gene transcription and 
protein expression. In general, many gene therapeutic approaches aim to replace, add or edit 
the mutated gene, either given systemically or as ex vivo cell therapy. Even if only the coding 
part of a gene sequence is used therapeutically, the size in many cases involves several kilo 
base pairs (kb), which normally require the use of viral vectors for efficient gene transfer (8). 
In contrast, non-viral gene delivery strategies lack certain risks associated with viral systems 
such as insertional mutagenesis, instead taking advantage of various transfection methods, 
nanoparticle formulations or complexes with targeting moieties to reach the desired tissue or 
cell in vivo (2).  
During the past ten years and most recently, the field of gene editing using targeted 
endonucleases has made some impressive progresses. The concept relies on the precise 
targeting of sequences in the genome for the direct editing of DNA. Following strand breaks 
and the subsequent repair, these approaches either introduce point mutations or aim at 
transgenic integration of a larger sequence of the desired DNA (9). The most promising 
 2 
techniques used are Zinc finger nucleases (ZFN) (10-16), Transcription activator-like effector 
nucleases (TALENs) (17-21), and Clustered, regularly interspaced, short palindromic repeats 
(CRISPR) together with a CRISPR-associated (Cas) protein (22-24). These techniques have 
made it possible for the gene-editing concept to advance into a clinical setting for various 
disorders such as infection, inflammation and cancer (25, 26). 
The DNA targeting approach also includes modulating the transcription of the gene, by using 
oligonucleotides (ONs) or other molecules capable of inducing, stalling or blocking of the 
polymerase activity. Targeting RNA for correction or replacement has also been heavily 
pursued both in academia and in industry (27-29). Finally, the protein itself can be targeted 
using ONs that block signaling or other undesired interactions from a mutated or 
dysfunctional protein (30, 31). This thesis examines the effect of DNA binding therapeutic 
ONs and the use of non-viral delivery applications for specific cell targeting. 
1.2 THERAPEUTIC OLIGONUCLEOTIDES 
ONs are linear polymers of nucleic acids and their analogues, usually between 8-50 bases in 
length. Using ONs for therapeutic purposes goes hand in hand with the development and 
understanding of gene regulation and nucleic acid chemistry in general, and dates back to the 
1960s (6), beginning with the discoveries of the 2´-fluoro (2´-F) and 2´-O-methyl (2´-O-Me) 
sugar modifications providing increased DNA and RNA binding affinity and resistance to 
degradation by nucleases, and the phosphorothioate (PS) backbone substitution for prolonged 
halflife and bioavailability (32-35). Later during the 1970s and 1980s, technical land-
winnings and the possibility for automated synthesis of longer ONs (36-38) together with the 
introduction of the antisense concept (39-41), the advantages of using ONs in therapeutic 
strategies became more and more evident. At present, an expanded use of ONs in different 
settings exists, taking advantage of various cellular control mechanisms for modulating gene 
expression (42, 43). Together with protein binding ONs, figure 1 summarizes the most 
advanced techniques used at the RNA level (Antisense approaches). 
1.2.1 Antisense oligonucleotides 
In Antisense ON (AON) applications, gene expression can be modulated after AON binding 
primarily to a messenger RNA (mRNA) target, even though other RNA targets are possible 
including non-coding and regulatory transcripts. Depending on the mode of action, 
modulation of expression can occur through inducing enzymatic cleavage of the target 
mRNA or by the steric blocking of translational events (29, 44). Enzymatic cleavage of the 
mRNA can be mediated by activation of RNase H, capable of recognizing DNA:RNA 
duplexes. For optimal RNase H-recruited cleavage, typically the AON “gapmer” design is 
applied where the AON has a gap of six to eight DNA nucleotides (nts) surrounded by 
chemically modified nts for enhanced target binding and stability (45, 46). The RNase H-
inducing strategy is one of the most mature AON technologies, and constitutes a major part 
of AONs in clinical development at present. 
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Another method used for inducing cleavage and subsequent degradation of the target mRNA 
is by taking advantage of the RNA interference (RNAi) pathway in which small interfering 
double stranded (ds) RNA (siRNA), consisting of a guide and passenger strand, is loaded into 
the protein complex known as RNA-induced silencing complex (RISC), after which the 
siRNA looses its passenger strand (47). One component of RISC is Argonaute 2 which is the 
enzyme responsible for the cleavage of the target mRNA after its association to the RISC 
complex and the complementary siRNA guide strand. siRNAs tend to tolerate modified 
ribonucleotide incorporations to a lesser extent. For example, when placed in the passenger 
strand modified nts can impair its degradation (48). Nonetheless, siRNA has been made more 
stable and efficient using modified bases at optimized positions, for instance in a design 
called “internally segmented siRNA” (49, 50). In general, changes to the phosphate backbone 
seems to be more tolerated, and alternating modified bases with unmodified RNA has been a 
quite successful approach (51).  
ASOs can also be designed to inhibit RNA processing by sterically blocking regulatory or 
translational events. This ASO category include splice switching ONs (SSOs) (52, 53), 
translational arrest ONs (54), anti-microRNA (anti-miR) ONs (antagomirs) and miR mimics 
(55). Recently, some success at inducing translation by ASOs targeting regulatory sequences 
in the 5´ UTR region of certain mRNAs has also been made (56). All these approaches have 
in common that they bind to RNA and hinder regulatory factors (or miRs) from recognizing 
and binding to their target sequence.  
1.2.2 Anti-gene oligonucleotides 
It is generally believed that anti-gene ONs (AGO) could be used to modulate gene expression 
at the DNA level by either interfering with transcription factor binding or by stalling the RNA 
polymerase during transcription (50, 57-59). In addition, AGOs have been used to induce or 
increase transcription from the displaced strand in DNA, which forms a so-called “D-loop” 
after AGO binding to the opposite strand (60). In an alternative approach, the AGO was 
shown to act in a similar way as a regulatory non-coding (nc) RNA, capable of binding to 
antisense transcripts that overlap the promoter region of the targeted gene. This can lead to an 
effect on gene transcription as the ON can act via steric blocking or a mechanism similar to 
RNAi (61, 62). At present, there is strong evidential support for the theory that AGOs can 
directly invade or bind chromosomal DNA and block transcription (63, 64). This thesis will 
focus on DNA binding AGOs. 
Some of the earliest attempts to target the genome involved the use of Peptide Nucleic Acid 
(PNA) analogues (65, 66), which were further modified and developed to increase their 
ability to bind DNA and affect gene transcription (67-69). Since then, different anti-gene 
strategies involving ONs have evolved using novel chemistries, where most bind to their 
target sequence by either i) forming a triplex via Hoogsteen (HG) interactions or by ii) strand 
invasion of the DNA double helix via WC base-pairing, or iii) through a combination of HG 
and WC binding by the use of a clamp construct. 
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Figure	1.	Different	antisense	and	protein	binding	strategies	for	ONs.	(1)	Endosomal	binding	of	toll-like	 receptors	 (TLRs).	 (2)	 Small	 interfering	 RNAs	 (siRNAs).	 (3)	 Micro-RNA(miR)	 mimics.	 (4)	Antagomirs,	for	endogenous	blocking	of	miRs	sterically.	(5)	Gapmer	Antisense	ONs	(AONs)	for	inducing	RNase	H	degradation	(steric	block	ONs	also	exist).	(6)	Aptamers,	for	binding	and	affecting	proteins.	(7)	Splice	 switching	 ONs	 (SSOs).	 Reprinted	 from	 ref	 (6)	 with	 permission	 from	 Mary	 Ann	 Liebert	 Inc.	publishers.	
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Several chemical modifications used in ASOs can also be employed in the design of AGOs to 
achieve higher target affinity and DNA complex stability. These aspects of AGO binding are 
addressed in more detail later in the thesis.  
Given the increased complexity compared to RNA when targeting DNA in its genomic 
environment, the requirements for successful transcriptional manipulation place a heavier 
demand on the AGO used. First, like SSO approaches, the AGO needs to be delivered to the 
nucleus. In addition, once binding has occurred, the AGO also needs to be capable of i) 
staying bound, competing with regulatory factors and proteins, and ii) if binding through WC 
interactions, competing with reformation of the dsDNA, and iii) withstand the polymerase 
during transcription. Thus, the AGOs must have enough affinity to increase the probability of 
binding to the target, and at the same time have minimal off-target effects in the genome and 
complementary RNA. This balance will greatly affect success, and AGO strategies will also 
ultimately face the same challenges as ASOs when it comes to cellular targeting, delivery and 
bioavailability. 
Successful ON binding of chromosomal DNA is a highly dynamic process depending on 
several factors. When active gene transcription occurs, the DNA in this region forms a less 
densely packed structure within the chromatin, which in combination with the dynamic 
breathing effect induced by supercoiling and stand separation by RNA polymerases, creates 
an environment favorable of ON binding (70, 71). WC-binding AGOs are typically single 
stranded and invade DNA at these transiently accessible regions formed mainly during 
transcription. 
Triplex forming ONs (TFOs) can bind to the major groove of the DNA double helix, which 
has been explored in different applications, such as transcriptional activation (72), blocking of 
transcription (73-76), recruitment of transcription factors (77, 78), fluorescent in situ 
hybridization of repetitive chromosomal regions (79) and TFO-padlock mediated tagging of 
DNA fragments (80). TFOs can even bind to DNA at transcriptionally silent loci, however, 
binding was dramatically increased upon targeting actively transcribed genes (81, 82).  
Another class of AGO is the Zorro-LNA, which invades supercoiled DNA and 
simultaneously binds to opposite strands forming Z-shaped structures by WC binding. The 
Zorro-LNA has been shown to invade and bind two adjacent target sites in supercoiled DNA, 
and further shown capable of blocking transcription (83). Since then, the Zorro-LNA has 
been extensively developed using different linkers and chemistries (84). The first generation 
of Zorro-LNA had the two arms connected through a sequence complementary linker to 
which both arms could hybridize. Later, the efficacy was improved by using chemical linkers 
such as the double HEG-linker, which showed higher strand invasion capacity (see figure 4G 
and ref (84)). This single stranded Zorro-LNA needs to be synthesized using reverse 
phosphoroamidites, addressed in more detail later in connection to paper I. Examples of AGO 
binding double-stranded (ds)DNA are shown in figure 2. 
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Figure 2. Different principles of dsDNA binding using AGOs. A shows the invasion using single stranded 
AGO, B shows TFO binding, C shows the binding and invasion using the combined TFO and strand invading 
AGO and D shows the Zorro-LNA binding concept. 
1.2.3 Aptamers 
Aptamers are ONs that interact with molecules through their ability to form secondary 
structures, allowing the aptamer to selectively bind to its target. The first aptamers were 
developed in the early 1990s (85, 86), and since then a substantial amount of both RNA and 
DNA aptamers have been developed, some of which have reached clinical trials (6). 
Aptamers commonly serve as ligands to proteins and receptors and are developed using the 
systematic evolution of ligands by exponential enrichment (SELEX) process in which the 
affinity of a large pool, or library, of RNA sequences are exposed to a target protein during 
repeated rounds of binding selections intermixed with PCR amplification, until only the most 
potent aptamer remains. The SELEX technology has been developed greatly in the last 
decades, introducing methods such as cell internalization-SELEX (87), where the aptamer 
library is enriched together with whole cells, and cell-SELEX combined with high throughput 
screening (HTS) (88, 89), and in vivo-SELEX trying to assess potent aptamer sequences in 
living organisms (90). These approaches typically employ post-SELEX modifications to 
enhance their stability and nuclease resistance (91, 92).  
Even though highly successful in obtaining aptamers with great affinity for various proteins, 
the early SELEX based approaches selecting for binding in solution sometimes did not 
directly correlate with effects in vivo due to conformational differences in protein binding. 
This was to some extent overcome by using the cell-based SELEX approaches in which the 
aptamers were enriched in an environment closer to physiological conditions, thus providing 
binding kinetic parameters during natural protein foldings (92). 
Despite some promising and successful aptamers being generated through cell-based SELEX, 
obtaining good clinical effects still remains a major hurdle in many cases. Adding to the 
complexity is the fact that higher number of rounds during SELEX can introduce selection 
bias. Some sequences will gain evolutionary advantages (93), either by sequence 
composition, structural conformations or stability (92). These can be more potent than 
components enriched in previous rounds. However, recently, attempts have been made to 
discover potent aptamers in early rounds in complex pools using post-SELEX based HTS 
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characterization combined with deep sequencing (94). Using aptamers for the specific uptake 
in cells is discussed further below. 
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1.3 OLIGONUCLEOTIDE CHEMISTRY  
1.3.1 Oligonucleotide synthesis 
With the introduction of automated synthesis of ONs in the 1980s, the ability for therapeutic 
applications and related mechanistic studies grew enormously (37, 38). The synthesis is based 
on the stepwise introduction of special nucleosides carrying an N′,N′-diisopropyl 
phosphoroamidite group attached to the 3´-hydroxyl of the sugar, with all funcional groups  
protected before synthesis. Through a series of deprotection, coupling and capping, each new 
phosphoroamidite nucleoside is added to the previous at the 5´-hydroxyl group, the first unit 
being attached to solid support made of Controlled Pore Glass (CPG) at its 3´ end. In the final 
step the nt attached to CPG is released and deprotected, yielding a single stranded ON that 
can be purified using HPLC techniques and qualitatively assessed by mass spectrometry 
(MS). 
When producing ONs containing different modified nts, the majority can be commercially 
obtained and introduced as phosporoamidites during synthesis. More complex ON synthesis 
can in some cases require some custom separate modifications for the introduction of the 
desired phosphoroamidite. A special case relevant to this thesis is the requirement of reverse 
phosphoroamidites when connecting two ONs of different polarity, such as 3´-5´- 5´-3. This 
has been successfully applied when synthesizing single stranded Zorro-LNA containing 
different synthetic linkers such as an extended hexaethylene glycol (HEG) linker connecting 
the two ONs (see figure 4G) (84). However, only normal reverse phosphoroamidites of non-
modified nucleotides are commercially available. Thus, this requires rather complex and 
expensive in house synthesis of such building blocks, which is why other strategies are highly 
desirable for reversing strand polarization.  
1.3.2 Click chemistry 
One alternative to using reverse phosphoroamidites to connect two Zorro arms with different 
polarities is to link the arms post synthesis using 1,3-dipolar cycloaddition or “click” 
chemistry (see figure 4H) (95). This approach can efficiently join a terminal alkyne group to 
an azide group under aqueous conditions using Cu(I) as a catalyst, and has been widely used 
in different settings since it was reported in 2002 (96-98). Five years later, a copper-free click 
chemistry procedure was published using a substituted cyclooctyne with similar high 
coupling efficiency (99). This group however, is much more expensive compared to the 
alkyne group used in Cu(I)-mediated click chemistry, but has more interesting applications in 
vivo since Cu(I) is not needed for the click reaction to occur.  
1.3.3 Base and sugar modifications 
Improvements in ON stability and target affinity were early identified as major factors for the 
successful use of ONs as modulators of gene expression. Unless stability and protection can 
be achieved through ON structure, chemically modified nts are needed to prevent enzymatic 
cleavage and also for increasing target affinity. Indeed, the cells’ own modification of natural 
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ribonucleotides provides a crucial fundamental mechanism to prevent degradation, such as 
the epigenetically important methylation of cytosine in DNA (100), or the many post-
transcriptional RNA modifications that act as stabilizing or structural components important 
for folding of the transcript (101, 102). The therapeutic ON platform takes advantage of some 
of these or related base modifications, such as the pseudoisocytidine (103). The other large 
group of modifications involves the sugar at the 2´-position (see figure 3). This affects the 
ribose conformation to a north or C3´-endo like state, which gives greater binding affinity 
mimicking the A-conformation in duplex RNA.  
1.3.4 2´-Fluoro- and 2´-O-Methyl modifications 
The 2´-deoxy 2´-fluoro (2´-F) was the first sugar modification introduced in 1964, which later 
was shown to provide higher duplex stability and increased nuclease resistance compared to 
unmodified nucleotides (104, 105). The 2´-O-Methyl (2´-O-Me) modification adds increased 
binding affinity in a similar way, and both have been extensively used since then to enhance 
ON design, even though they were ultimately found not to have optimal drug like metabolic 
stability, unless combined with the phosphorothioate (PS) backbone described below (106).  
1.3.5 Locked Nucleic Acids 
Another important sugar modification is the Locked Nucleic Acid (LNA) in which a 
methylene bridge connects the 2´ oxygen to the 4´ carbon, which creates a conformational 
constrain, forcing the ribose into a near C3´-endo state which gives it an RNA-like 
conformation (107, 108). LNA nucleotide phosphoroamidites were developed independently 
in 1997/1998 by Wengel and Imanishi, and could be incorporated during ON automated 
synthesis (109, 110). LNA can increase the thermal stability of a duplex with 2-8°C per nt 
depending on the number of incorporated LNAs and which base is involved in forming the 
WC base pair (111). Much of the increase in affinity stems from an energetically favorable 
conformation that also involves base stacking (112, 113). TFOs containing LNA were shown 
to be more stable than their DNA counterparts due to lower dissociation rates, however, 
TFOs containing only LNA are not able to form a triplex at all (114-116).  
In addition to binding affinity, LNA-containing ONs can also increase resistance to 
degradation by enzymes present both in serum and in the cell. Studies show that introducing 
at least two LNA nts in the 3´ end of the ON increases protection from 3´ exonuclease 
activity (117). As with other 2´-modifications, stability can be much enhanced if LNA is 
combined with PS backbone modification (118, 119). The combination with PS backbone 
also greatly improves the pharmacological and cell internalization properties of the ON (120). 
Thus, LNA-containing ONs have successfully been used in different therapeutic applications 
including antisense (121), siRNA (122, 123), SSO (124-126), anti-miR (127), and aptamers 
(128). 
Several analogues have been derived from LNA. The 2´-amino-LNA provides a convenient 
chemical handle to which other groups can be conjugated, while at the same time maintaining 
the conformational properties associated with bridged nts (129). Examples of functional 
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groups attached to LNA ONs include moieties introducing a positive charge for enhanced 
duplex and triplex stability (130, 131), and cholesterol for increased efficiency of a miR 
knock down probe (132). Data suggest that 2´-amino-LNA seems to destabilize triplexes. In 
contrast, the use of 2´-glycylamino-LNA can stabilize triple helices by 1.7-3.5 °C per 
substituted nt (133).  
Ethylene-bridged Nucleic Acids (ENA) nts are locked in the north conformation just as LNA, 
but instead the methylene bridge is exchanged for ethylene (134). ENA does not stabilize 
duplexes as good as LNA, however, triplexes can be readily stabilized using ENA containing 
TFOs (135).  
1.3.6 Unlocked Nucleic Acids 
A special case of novel modifications introduced in the last years is the Unlocked Nucleic 
Acid (UNA) (136), which in contrast to LNA lacks both constraint and the bond between 
C2´and C3´ in the ribose ring (see figure 3). Due to increased flexibility of the phosphodiester 
(PO) backbone, UNA reduces the thermal stability when hybridized to both DNA and RNA 
(137, 138). Depending on the nt position, the decrease in stability is between 1-10°C, with 
greater effect in the center of a duplex and less effect towards the ends (139). Applications 
where UNA has been found useful includes its incorporation into siRNA to reduce off-target 
effects by destabilizing involved regions (140), and change polarity of the RISC-loaded 
siRNA strand (141), and in aptamers where it can reduce conformational restrain in loop 
regions which increases aptamer folding kinetics and efficacy (142). 
1.3.7 Phosphorothioate and backbone modifications 
Also of great importance are the backbone modifications used to enhance ON performance 
(see figure 3). The most mature of these modifications is the inclusion of sulfur instead of 
oxygen in the PS backbone, changing the interactions and stability of PS-containing ONs. 
The PS group provides a chiral center, thus two stereoisomers exist called Rp and Sp in a 1:1 
ratio giving the ON its characteristic properties (143). The simultaneous ability to resist 
nuclease degradation and at the same time allow other enzymatic activity (such as RNase H), 
is perhaps the most striking enhancement the PS modifications give. This can be traced back 
to the stereoisomeric properties of such PS ONs, the Rp configuration gives higher binding 
affinity to RNA and induce RNase H, compared to the Sp form that does not, but instead 
promotes higher nuclease stability (144). However, it has been shown that the combination of 
Rp and Sp form is desirable for antisense applications (145, 146). Because of these 
properties, PS ONs have been used with success in many different settings. Most importantly, 
they have good pharmacological properties since the bioavailability and serum stability is 
high due to plasma protein binding, and cellular uptake is enhanced compared to PO-
containing ONs (144).  
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1.3.8 Peptide Nucleic Acids 
PNA represents a potent nucleic acid analogue where the sugar phosphate backbone has been 
replaced by N-(2-ethylamine)glycine polyamides (65). The achiral PNA oligomers are highly 
flexible and have a neutral backbone, which give them good hybridization properties and 
high in vivo stability (147). Under low salt conditions, PNA have had excellent properties 
binding to DNA, however, at physiological salt concentration this effect is much reduced 
(148). Single stranded PNA oligomers experiences some issues regarding solubility under 
aqueous conditions where it readily forms aggregates (149), especially when GC content is 
over 60% and if the oligomer is longer than 12 nts (150). However, low solubility can be 
counteracted by introducing positively charged peptides, such as lysines. Additionally, due to 
the lack of charges, the PNA oligomers are not well taken up by cells; they are often 
combined with various methods to assist the oligomer internalization, such as electroporation, 
liposomal transfection agents or by direct conjugation to Cell Penetrating Peptides (CPPs) 
(151). Allthough, over the years many different PNA analogues have been synthesized that 
can overcome some of the limitations owning to poor solubility and uptake (150). 
PNA has been used to target RNA in cells with some success, including inhibition of 
translation (152), splice correction (153), and as antimiRs (154). The antimiR approach was 
recently also successfully combined with CPPs for the delivery to breast cancer cells and a 
lymphoma animal model directed towards mir-221 and mir-155 respectively (155, 156). 
These latest studies provide a good example to the fact that PNA could still be a promising 
chemistry in conjugation to various active biomolecules.  
In anti-gene approaches, PNA can bind to DNA both by strand invasion and triplex formation 
via strand displacement (157). Due to less electrostatic repulsion of the dsDNA to the 
uncharged PNA, binding is strong compared to negatively charged ONs, but neutral pH is not 
favoring triplex formation in polypyrimidine TFOs containing many Cs, unless 
pseudoisocytidine is used introducing a hydrogen bond without the need for the C protonated 
state (158). Also of interest is the bisPNA construct, in which two polypyrimidine PNA ONs 
are connected via a linker region to form a clamp. These constructs effectively bind DNA 
through WC and HG interactions under low salt conditions, and by extending this construct 
with a tail sequence it could circumvent the need for long polypurine stretches (159, 160).  
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Figure 3. Structures of natural and modified nucleotides.  
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1.4 INTERCALATORS AND DNA LIGANDS 
Intercalators, or molecules that can stabilize different nucleic acid structures non-covalently 
by insertion between two adjacent bases, constitute an efficient approach for the improvement 
of DNA targeting and binding (161). According to the first model proposed in 1961 based on 
acridine, the binding usually occurs non-specifically by hydrophobic and electrostatic π-π 
interactions, leading to a change in the double helix by decreasing the helical twist (162). 
Since then, many intercalators have been synthesized and several have even become drugs on 
their own as anti-cancer agents (163, 164), and when attached to ONs they get the target 
sequence-specificity otherwise missing. 
One example of ONs combined with intercalators is the use of twisted intercalating nucleic 
acid (TINA). This compound can be incorporated at different positions in the ON, creating an 
increase in the thermal stability of both duplexes and triplexes (165). It stacks with the 
nucleobases by its aromatic ring and its stabilizing ability is much dependant on where it is 
placed in an ON sequence. For instance, when placed terminally, both ortho and para-TINA 
(figure 4E+F) gave higher stability for an antiparallel duplex compared to when placed at 
other positions (166). 
A special case of DNA binding low-molecular weigtht (small) molecules is the G-quadruplex 
(G4) ligands, capable of stabilizing G4 DNA and RNA structures by groove binding and 
intercalation. These are typically planar, aromatic molecules and many can have selective 
binding of certain preferred G4 motifs (167). Some early-discovered G4 ligands are the 
macrocyclic compounds such as porphyrins and their derivatives (168). One of the most 
studied porphyrins is TMPyP4 (figure 4D), which was shown by Hurley et al to be capable of 
stabilizing G4 structures present in the telomeric DNA sequence and inhibit telomerase 
activity (169, 170). It was shown to stack to the G tetrads, and thereby stabilizing both intra 
and intermolecular G4 structures (171). 
Another example of small molecules capable of stabilizing G4 structures is ellepticine and its 
derivatives (for examples, see figure 4A-C). Ellipticine has been investigated as a potent 
antitumoral agent, and it was also found to be able to intercalate into DNA (172). Soon it was 
realized that it could stabilize G4 structures, after which some derivatives were synthesized to 
enhance this interaction and create more specific stabilization of various motifs (173, 174).  
The stoichiometry of G4 ligands and binding mode to their target can vary considerably. For 
instance, TMPyP has been shown to bind four, and even five molecules per G4 structure 
(175, 176). Thus, careful investigation of G4 ligand binding mode is an important parameter 
to assess, since any additional excess of ligands present can result in non-specific interactions 
(177). 
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Figure 4. Different intercalators, G4 ligands and linkers. A Ellipticine and derivatives B 1-ChE and C 1-
OxE, D TMPyP4, E ortho-TINA, F para-TINA, G 2xHEG linker used in some single stranded Zorros, H Click 
chemistry linker used in the novel Zorro-LNA constructs, I the M3-linker used in bis-LNA. 
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1.5 NON-VIRAL OLIGONUCLEOTIDE DELIVERY 
Naked ONs are usually not suitable for in vivo cellular delivery, even though, as discussed 
above, the PS-containing ONs have quite high bioavailability due to their binding to serum 
proteins (178). The main concern lies in gaining high enough local accumulation for cell 
internalization to have the wanted biological effect. For this, normally a delivery platform is 
utilized which could aid in the uptake and at the same time give protection and/or stealth 
properties to the ONs during systemic circulation. Also of importance, this delivery vehicle 
should not stimulate immune responses, in order to promote multiple dosing and the efficacy 
of the ON drug.  
Non-viral delivery methods can be divided into non-targeted and targeted approaches and 
they both include direct conjugation or formulation with various entities that can promote cell 
internalization. Conjugated ON approaches are often more defined and predicable in terms of 
chemical identity and size. Particle formulations on the other hand, show increased 
polydispersion and heterogeneity and are more prone to be affected by environmental 
parameters, such as storage, handling and mixing. This variability can be reduced by the use 
of microfluidic systems, which are capable of rapidly producing more defined particles and 
complexes (179). 
1.5.1 Cellular entry 
ONs and nanoparticles are normally entering cells by endosomal pathways. These are 
classically assigned to various receptors and entry mechanisms such as the clathrin- 
dependent and independent pathways, pinocytosis, phagocytosis, macropinocytosis and 
caveolin-dependent and independent uptake routes (180). Following encapsulation the cargo 
needs to have some ability to escape the endosomal entrapment, which otherwise could lead 
to its degradation after fusion with lysosomes, or export from the cell via late endosomal 
recycling and various vesicle trafficking (181). The endosomal environment undergoes a 
general reduction in pH during its maturation, and entrapped cargo can escape at certain time 
points, through mechanisms that are largely unknown.  
In the context of lipoplex-ON formulations, some evidence characterize the endosomal 
escape of ONs as non-pH dependent, cation-induced disruption of the lipid membrane 
resulting in the displacement of anionic lipids from the cytoplasmic side to the inner core 
facing the lipoplex. This in turn drives the increased lateral diffusion and ion paring with the 
lipoplex cations finally releasing the cargo ON into the cytoplasm (182). The details 
regarding these mechanisms remain to be shown, and will depend on many different variables 
such as ON/vector chemistry, charge, particle size and the type of cell being studied. 
Attempts to enhance endosomal escape by construct design has been pursued, such as the 
recent chemically enhanced Endosomal Escape Domain (EED) platform which was shown to 
benefit the cytoplasmic delivery of therapeutic ONs (183).  
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1.5.2 Non-targeted delivery approaches 
Agents that promote cellular entry in a non-specific manner to deliver ONs have been 
explored with increased intensity in the recent years. A major class of such non-viral delivery 
vectors is the nanocarriers. Cell-penetrating peptides (CPPs) constitute a subclass used for 
efficient delivery of nucleic acids to cells and tissues. By either direct cargo conjugation or as 
nanoparticle formulations, CPPs can typically carry large biopolymers and therapeutic ONs 
of different sizes into cells both in vitro and in vivo (184, 185). Since its first usage in 
conjugation with PNA, the CPP concept has been much further developed and is now being 
used in combinations with different therapeutic ONs.  
The basis for the mode of action is a cationic peptide, under 30 amino acids in length, 
harboring varying degrees of amphiphatic properties that aid in the ON internalization 
through endocytotic pathways (186). ON chemistry compatible with CPP conjugation is in 
general restricted to charge-neutral chemistries such as PNA or morpholino nucleobases, 
otherwise charge interactions between the positive peptide and negative ON would 
complicate the synthesis and physiochemical properties of such entities. One example of CPP 
formulation, also used in paper II of this thesis, is the Pepfect14  (187), which is capable of 
forming nanocomplexes with ONs with the same efficiency as commercial lipoplex 
formulations for the delivery of ONs into a number of cell lines (188). 
Another important nanocarrier is based on lipid nanoparticles. Cationic lipoplexes are 
efficiently forming nanoparticles with ONs by condensation, and this vehicle class has been 
used extensively for ON delivery (189-192). Cationic lipoplexes usually consist of a mix of 
polethylenimine (PEI) with lipids and other helper components that can add to the efficacy, 
such as cholesterol and 1,2-dioleoyl-3-trimethylammonium-propane (193).  
However, the lipoplexes are known to induce various degrees of toxicity depending on the 
exact formulation composition, which is why they are generally not pursued as in vivo gene 
delivery vehicles. In comparison, neutral liposomes have a better cytotoxic profile and 
typically consist of charge-neutral lipids such as cholesterol that interact to a lesser extent 
with serum proteins. They are however, compared to the lipoplexes, more pH-dependent in 
order to achieve efficient endosomal escape (194). Recent advances for lipid nanoparticle 
formulations and composition have resulted in several ongoing clinical studies such as the 
stable nucleic acid lipid particles (SNALPs) by Tekmira, and the Smarticles by Marina 
Biotech (195). 
1.5.3 Targeted delivery approaches 
Strategies for targeted delivery of ONs rely on the attachment of molecules and ligands that 
promote specific uptake by cells and tissues, either directly to the ON itself or to the surface 
of a delivery vehicle. Specific uptake and effect in the liver following administration have 
been reported for cholesterol siRNA conjugates (196), also used for siRNA targeting HTT 
mRNA in an animal model for Huntington´s disease (197). By conjugating siRNA to alpha-
tocopherol, tissue-specific targeting and reduction of ApoB production in the liver was 
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achieved (198). Another highly successful lever-targeting approach is based on the 
interaction between the asialoglycoprotein receptor (ASGR) and the multivalent N-
acetylgalactosamine (GalNac) group (199), which has been successfully conjugated to siRNA 
in a trivalent form (200). The concept has been further developed by Alnylam 
Pharmaceuticals and the GalNac conjugates have now advanced to phase III in clinical trials 
and provide a promising and potent platform for specific targeting and delivery of therapeutic 
ONs to the liver.  
Folate conjugated ONs and nanoparticles have been evaluated in different therapeutical 
settings. The concept is based on the specific recognition and internalization by binding to the 
folate receptor overexpressed on the surface of certain cancer cells that efficiently take up the 
folate conjugates, which normal cells do not since they have a much lower folate receptor 
density (201, 202). Another receptor overexpressed on tumor cells is the transferrin receptor, 
and by conjugating transferrin to nanoparticles containing siRNA against EWS-FL 11, 
Ewings sarcoma cells were efficiently targeted and knocked down in vivo following an 
intravenous dose of 2.5 mg/kg (203). Conjugating nanoparticles using monoclonal antibodies 
has been shown to be an efficient way to internalize ON cargo in a specific manner. For 
example, siRNA has been delivered using this strategy to melanoma cells (204), activated 
leukocytes (205), and malignant B-cells (206). Using aptamers for ON specific cell targeting 
and internalization constitutes a well-studied delivery platform, ranging from conjugates with 
ONs, small molecules, various nanoparticles and even antibodies (207). Typically, an 
overexpressed cell surface receptor is targeted through the use of various SELEX approaches.  
1.5.4 AS1411 and oligonucleotide delivery 
A notable exception from the use of SELEX in aptamer development is AS1411, an aptamer 
used extensively as a targeting moiety in the last decade. It was discovered when screening 
for antiproliferative effects of some guanine-rich TFOs in cancer cell lines using naked 
delivery (208). The control ON used in these experiments was AS1411, and it unexpectedly 
showed remarkable antiproliferative effects and resistance to degradation even though 
consisting of non-modified DNA with a 3´ protecting group. Later it was found that these 
properties were due to the formation of G-quadruplex structures and the aptamer´s ability to 
bind nucleolin (NCL) receptors overexpressed on the cell surface of many cancer cells. After 
this, it underwent extensive testing and even reached clinical phase II as an anti-turmoral 
agent, where it was later discarded due to lack of efficacy (209).  
Since then, the interest in AS1411 has turned from a therapeutic to a delivery platform, since 
many cancer cells efficiently and selectively internalize it via the NCL receptor. Various 
attempts to shuttle cargo into cells have been made, including small molecules (210, 211), 
nanoparticles (212), antimiRs (213), and SSOs (214). In paper IV, the direct conjugation of 
LNA-ONs to AS1411 and their specific delivery to cancer cells is investigated (215). 
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1.6 DNA STRUCTURE AND ORGANIZATION 
Since the famous description of the double helix structure by Watson and Crick in 1953 
(216), in the close footsteps of Wilkins (217), and Franklin (218), much has been discovered 
related to DNA in terms of structure and function. The four DNA nts had already been 
uncovered together with Uracil in 1881 (219), but their true function and properties were 
described shortly after the seminal paper presented by Watson and Crick. Now, the landscape 
of the genome and its components are known in more detail, and additional discoveries are 
made each year.  
1.6.1 The double helix 
The DNA double helix consists of two polynucleotide strands containing the four bases 
cytosine (C), guanine (G), adenine (A) and thymine (T), organized in a dynamic helical spiral 
held together through non-covalent stabilizing and destabilizing forces. The helical shape is 
created when the polynucleotide strands with opposite polarity interact through their 
hydrophobic inner core, consisting of the nucleobases, and the hydrophilic outer surface, 
outlined by the phosphates of the strand backbone. These phosphate groups are 
electrostatically repelled by each other, both from groups on the same strand, and from the 
phosphate backbone of the opposite strand (220). This creates a destabilization of the helix, 
which is countered by the presence of shielding cations in the surrounding aqueous solution 
(221).  
The higher the ion concentration the more of a shielding effect and stabilization of the double 
helix occurs. The nucleobases facing each other contribute to the helical stabilization by 
forming planar pase pairs (C-G with three and T-A with two hydrogen bonds) and, more 
importantly, by stacking through π-interactions between the aromatic rings of the bases. The 
stacking force is the major contributing factor to the observed 3.4 Å distance between the 
bases (222). Purines are able to stack with higher efficiency compared to pyrimidines due to 
their larger surface and polarization properties (220). As mentioned already, the DNA 
stability is also affected by the various metal ions and water molecules, which all contribute 
to the helix formation (220). 
DNA can exist in different conformations depending on environmental factors and sequence. 
All double helical structures have in common the minor and major groove, which are pockets 
created due to the helical twist of the two antiparallel strands where the edges of the 
nucleobases are exposed. These grooves constitute the sites of sequence specific recognition 
and binding of proteins or nucleic acids, where the major groove has higher propensity for 
interactions due to a wider pocket (223). Three characteristic DNA conformations exist for 
the DNA double helix in the genome: B-DNA, A-DNA and Z-DNA. The shape is mainly 
determined by the sugar pucker conformation of the nts. 
B-DNA is the most abundant DNA conformation found under physiological conditions and 
has the typical symmetrical right-handed turning shape with 10.5 bases per turn and 23.7 Å in 
diameter. The bases are perpendicular in respect to the helical axis, and the sugar pucker is in 
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a C2´-endo conformation which, together with the anti-conformation of the bases, give B-
DNA its properties. 
A-DNA is also right handed but with C3´-endo conformation of the ribofuranose ring, tilting 
the bases slightly with respect to the helical axis. This also affects the number of bases per 
turn, which are now 11 with a wider diameter of 25.5 Å. Under low hydration conditions the 
major groove becomes slightly wider and water molecules are less prone to interact with the 
DNA, resulting in the A-DNA conformation. 
Z-DNA constitutes a much less organized form of DNA compared to A-DNA and B-DNA. 
Both C2´- and C3´-endo sugar puckers are present giving the structure a scattered impression. 
Z-DNA can be found in GC-rich regions and the helix is left-handed. 
Under certain conditions, the DNA can adopt other specific conformations with different 
characteristics and function, some of which are important for this thesis, as discussed below. 
1.6.2 The triple helix 
Shortly after the double helix structure was reported, a paper describing the triple helix was 
published in 1957 (224). But it was Karl Hoogsteen that published the paper showing the 
structural differences of triplexes compared to WC base pairing (225). Following these initial 
discoveries, many therapeutic investigations using TFOs were published (226), such as the 
interactions and sequence specific binding of TFOs to a double helix (227, 228). More 
recently, evidence of triplex formation in vivo has also been reported (229). In particular, 
intramolecular triplex structures, so-called H-DNA, are associated with certain diseases (229-
231).  
Triplex formation in DNA occurs through HG or reverse-HG mode of binding (figure 5), and 
requires the duplex sequence to be composed of polypurine/polypyrimidine stretches. A 
pyrimidine TFO, or third strand, forms HG hydrogen bonds with the purine bases of the 
duplex (figure 6A+B), through a mechanism known as “nucleation zippering” starting from 
the 3´extremity where it initially binds to 2-3 nts followed by a zipper-like binding of the rest 
of the TFO (232, 233). 
Atomistic data from X-ray crystallography, NMR and modeling suggest that triplexes adopt 
different forms than A-DNA or B-DNA. The major groove is wider in order to accommodate 
the third strand, and as a result, the minor groove becomes much more narrow (234, 235). 
The different modes of strand interactions in a triplex fall under three motif-categories 
depending on sequence and backbone orientation (figure 5A) (226, 236).  
(T,C)-motifs, or pyrimidine motifs (i), form when the third strand binds in antiparallel with 
respect to the duplex. Some of the Cs in the TFO need to be protonated in order for an 
efficient triplex to be formed and as a consequence, these triplexes are unstable at neutral pH 
(237-239). Thus, this type of motif requires either low pH, or the incorporation of a modified 
base such as pseudoisocytidine, discussed above. (G,A)-motifs (ii) forms reverse-HG 
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hydrogen bonds in an antiparallel mode of binding, and (G,T)-motifs (iii) bind either in 
parallel or anti-parallel with respect to the purine strand of the duplex. Both (G,A)- and 
(G,T)-motifs are called purine-motifs and since they do not contain C, they can form stable 
triplexes at neutral pH. Due to the presence of G bases, these sequences can also adopt G-
quadruplex conformations (240), discussed further below. Examples of WC and HG base 
pairing can be seen in figure 6A+B. 
 
 
Figure 5. Different structural motifs involving A triplexes and B quadruplexes. B also shows the centrally 
placed stabilizing monovalent cation (potassium or sodium), represented as a red ball. 
 
1.6.3 G-quadruplexes 
In 1962 it was shown that the G bases of a guanylic acid (GMP) could form a helix consisting 
of linear aggregates due to base stacking and base pairing between four different Gs in a 
planar tetrad (241). This G-quadruplex (G4) helix conformation was later confirmed in other 
situations and have since then been extensively studied both structurally and functionally. 
The structural stability of the planar G-quartets originates in the HG hydrogen bonding 
between the Gs at positions N1-O6 and N2-N7, and from a centrally placed monovalent cation 
(mainly K+, but also Na+ or NH4+), interacting with the O6 electron lone pairs facing the inner 
space of the quartet (see figure 6C) (242). When an ON consists of continuous G-stretches 
(separated by 1-7 other bases), it can adopt stable helical G4 conformations where the G-
quartets stack upon each other due to π-π interactions.  
Depending on the polarity and the number of strands involved, G4 structures can form inter- 
or intramolecular parallel and antiparallel conformations (Figure 5B). For parallel strands, the 
sugar conformation of the Gs are in anti, and in antiparallel they adopt the syn conformation 
(243). The glycosidic angle will affect the phosphate backbone orientation, which in turn will 
affect the wideness of the groove, resulting in wide grooves for parallel strands and narrower 
grooves for antiparallel strands. Bases outside of the G-stretches will form loop regions that 
connect the structure together, and depending on how many strands are involved in forming 
the G4, and if they run parallel or antiparallel, the loops can make turns on the same side or 
may cross the structure to continue on the other side. 
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G4 sequences have been extensively studied in vitro to assess their conformational properties, 
interactions with proteins and ligands, as well as their therapeutic target potential. Both RNA 
and DNA are capable of adopting G4 conformations. Their stability is related to the number 
of G repeats in the sequence, the type of ion and its concentration in the buffer (244). For 
instance, a sequence capable of forming both a triplex and G4, can be shifted more to a G4 
state if the K+ concentration is raised in relation to Mg2+ (245). In contrast, Mg2+ can 
destabilize a G4 at high concentrations, and K+ almost always give more stable structures 
compared to Na+. Also, the stability of G4s is affected by the loop sequence size, where 
longer loops give lower stability (245). However, RNA G4 seem to be much less affected by 
loop size, indicating higher stability and less polymorphism (246). 
The evidence for G4s in vivo and their potential biological role is under intensive 
investigation. Using bioinformatics and G4 sequencing methods, it has been estimated that 
potential G4 sequences in the human genome range from 300 000 to well above 700 000, 
depending on the number of other disrupting bases and loops in and between the G-stretches 
(247, 248). They seem to be distributed in a non-random fashion and are highly conserved 
between species, suggesting functional and evolutionary important roles for G4s (249). The 
G4 sequences are mostly found at telomeric regions followed by places such as promoters, 
intron/exon junctions, regions involving immunoglobulin class switching recombination, and 
the 5´- and 3´-UTR of mRNA (250). In addition, they have been shown to be associated with 
certain genetic diseases (251). 
With the exception of mRNA and telomeric regions, the other G4 sequences are present in 
dsDNA well packaged and hidden in chromatin. However, during transcription and 
replication, these regions are accessible and transiently single stranded, making it possible for 
the G4 structures to form, and it is also for this reason many of their functional roles in the 
genome seem to be connected to these events (250), such as the involvement in the regulation 
of DNA replication and epigenetics (252). A key factor to the functional roles of G4s in the 
genome is the folding kinetics, which has been found to take between milliseconds, as in the 
case of telomeric G4 sequences, up to several minutes when the folding/unfolding is directed 
by certain helicases or chaperones (250). 
To show that the folding of these structures exists in vivo, a few methods have currently been 
based on using antibodies capable of recognizing both G4 structural motifs (253), as well as 
selective ligands binding stabilizing G4 structures (254, 255). Also, very recently, a method 
to study the formation of RNA G4s in cellular extracts has been developed in which 7-deaza-
G RNA is used instead of regular Gs (256). These cannot form the required HG bonds seen in 
G4s, making it possible to study the presence of G4 in long RNA using combined with 
footprinting and G4 selective antibodies. 
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Figure 6. Examples of base pair interactions in different settings. A shows the Hoogsteen and Watson-Crick 
hydrogen bonding involving T*A-T, B shows the Hoogsteen and Watson-Crick hydrogen bonding involving 
C*G-C, C shows the Hoogsteen interactions in a G-quartet surrounding the central monovalent cation (M).  
 
1.6.4 Higher order of DNA structures 
DNA topology is highly regulated in the cellular environment. The genomic organization is a 
fundamental component of life and has direct impact on gene regulation and function. As 
outlined earlier in this chapter, the chemical surrounding of DNA constitutes the foundation 
for the organizational components in this complicated equilibrium. In addition, many proteins 
and enzymes are functional entities in this machinery and play major roles in the 
orchestration at both low and high hierarchical levels. The overall organization the genome 
are the chromosomes, which is comprised of the highly dynamic chromatin material, that can 
be further subcategorized in terms of DNA packaging. 
First, the DNA helix is negatively supercoiled, meaning a thermodynamic strain is introduced 
between two points that create an underwined state where the DNA contains fewer helical 
turns compared to the ideal B-DNA. The degree of supercoiling can be changed by the 
introduction of a break, or the relaxation by some other means such as through an enzymatic 
action. Indeed, the topoisomerases in control of these events are important during packaging 
and replication of DNA (257). The supercoiled DNA is further organized with more dense 
twists in structural units called nucleosomes, which consist of 146 bp DNA wrapped around 
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an octamer of 4 histone proteins (H2A, H2B, H3 and H4). These multiple nucleosomal units 
form an 11 nm thick fiber of bead-like units of the histone core and 200 bp DNA each. The 
organization of DNA in the nucleosomes is not random and seems to be governed by the 
accessibility of regulatory proteins to certain sequences (258). Also, the N-terminal tail of the 
histone proteins can be modified with various functional groups, which have been shown to 
affect chromatin structure and gene regulation, one example being the methylation of lysines 
(K) and arginines (L) on histone 3 (H3) (259).  
The DNA is compacted 7-fold when wrapped in the nucleosomal context, and about 100-fold 
when the nucleosomes are ordered in a 30 nm fiber, made possible by further coiling and 
loop formations. Since the overall compacting of DNA in the cell is greater than 10 000-fold, 
it clearly exist higher orders of DNA organization. Both 300 and 700 nm fibers have been 
defined in the 1400 nm dense structure of one mitotic chromosome, all made possible 
through the interaction and function of several proteins involved in chromatin organization 
and folding. 
The order of DNA packaging and the supercoiling of DNA will directly affect ON binding 
and strand invasion. For instance, in plasmids, the circular DNA used in this thesis for 
assessing and ranking strand invasion capacity of different ONs, negative supercoiling and 
the resulting dynamic effects such as DNA breathing make ON binding possible. Thus as a 
result, supercoiled DNA will in certain situations favor ON binding, something especially 
clearly demonstrated when comparing to invasion of relaxed DNA, which is more difficult 
(71). In the cell, these “open regions” are much more regulated and differ between cells at 
different time points in association to events that involve chromatin remodeling, such as the 
events involved in actively transcribed genes (260).  
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1.7 HUNTINGTON´S DISEASE 
Huntington´s disease (HD) is an autosomal dominant neurodegenerative, fatal disease, which 
is characterized by the progressive loss of motoric and cognitive functions. 5-10 in 100 000 
are affected and symptoms usually starts at 15-20 years before death. There is no curative 
treatment, although symptomatic treatment exists for the involuntary movements, chorea, 
that most patients suffer from (261). The disease mechanism behind HD stems from a gradual 
expansion of the CAG trinucleotide repeat region in exon 1 of the Huntingtin (HTT) gene, 
giving rise to a mutated HTT protein (muHTT) where the many polyglutamine repeats give 
the protein its gain-of-function toxicity and propensity for aggregation (262). More recently it 
has also been suggested that the muHTT mRNA could contribute to the pathology to a certain 
extent by sequestering factors and regulatory elements (263). In normal, healthy individuals, 
the CAG repeats usually do not exceed 20, but in patients when the expansion reaches above 
35 repeats, the symptom begin to appear and correlate well with the severity of the disease, as 
well as age of onset (261). Studies in mice have shown that HTT is important during 
development (264), but the function of HTT in the adult individual appears to be of less 
significance for normal physiological processes (265, 266). 
The CAG repeat sequence in the gene has been shown to make intrastrand self-interactions, 
creating branches of many small hairpin structures (267-269), which is also present in the 
mRNA (270). These hairpins are more extensively formed in regions with higher number of 
repeats (271), and are directly involved in disease progression. They are mechanistically 
connected to the CAG expansion process during DNA repair and replication by the 
introduction of asymmetric replication biases, as the polymerase is stalled on one strand at the 
repeats but can continue on the other, leading to the inclusion of new repeat loops as the 
replication process is restarted (272).  
1.7.1 Oligonucleotide treatment strategies 
Ever since the finding that HD symptoms may be reversed when muHTT was knocked out in 
a mouse model (273), much attention has been directed towards the reduction of the toxic 
protein. At present, several ON based therapeutic options are under intensive investigation. 
These strategies fall into two main categories, i) non-allele specific reduction of total HTT or 
ii) the allele-specific reduction of muHTT. The advantage of the non-allele specific approach 
is that one ON drug can target all HD patients and not just a patient subpopulation. On an 
RNA level, both these approaches have been tested using siRNA (274), SSO (275), ASO 
(both RNase H mediated and steric blocking) (276, 277), ZFN (278), RNAi and RNase H 
mediated approaches (279), and one ASO designed for the reduction of total HTT is currently 
investigated in a phase I/II clinical trial by Ionis Pharmaceuticals (280). 
ASO-mediated targeting of the repeats present in the mRNA has been evaluated and proven 
to give allele-specific effects due to the increased number of targets present on this allele 
(281). This strategy has been evaluated using different chemistries and can potentially target a 
  25 
broader patient population compared to other allele-specific approaches targeting single-nt 
polymorphisms (SNPs) (282). 
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2 AIMS 
The overall aim of this thesis is to optimize AGOs using novel chemical modifications and 
characterize their efficacy and delivery. More specifically this includes investigating AGOs 
with different modes of binding and the effect on specific uptake of AGOs with different 
chemical composition: 
- Developing a fast and efficient method for the connection of the two ON arms in 
Zorro-LNA in a 3’-5’-5’-3’ orientation using click chemistry, and evaluate their 
efficacy. 
- Optimization of single stranded AGOs targeting the trinucleotide repeats in HD for 
the downregulation of HTT and investigation of their DNA binding and specificity. 
- Characterization and DNA binding optimization of bisLNAs containing novel 
chemical modifications and intercalating molecules. 
- Using a modified nucleolin receptor targeting aptamer connected to modified ONs to 
study the effect on the specific uptake of the constructs and their efficacy in cells. 
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3 METHODOLOGY 
The following methods were used in this thesis to assess AGO effect, DNA binding or 
physiochemical characterization of the construct or its target sequence.  
3.1 GEL ELECTROPHORESIS 
In this thesis two types of gel electrophoreses are used to separate fragments of DNA and 
oligonucleotides, polyacrylamide gel electrophoresis (PAGE) and agarose gel 
electrophoresis. The separation in both cases depends on the size and structure of the 
fragments as they migrate through the polymer matrix at different rates. PAGE gives better 
resolution for smaller fragments (<1000 bp), while agarose gels are usually used for larger 
fragments. Also the percentage of the polymer in the gel, buffer composition and the time and 
magnitude of the supplied voltage will affect fragment migration along with any hybridized 
ON. These parameters need to be considered when assessing DNA binding of AGOs to target 
sequences as it can affect the result.  
In addition, the electrophoresis can be performed using denaturing or non-denaturing 
conditions. Non-denaturing, or native, gel electrophoresis refers to conditions in which the 
chemical environment of analysis can preserve ON secondary structures and hybridization 
products. In denaturing conditions, the gel is supplemented with a chemical capable of 
maintaining the separation of two hybridized ON strands or internal structures. Typically, this 
is achieved using PAGE containing 7% UREA in combination with heating the sample 
before loading and the addition of 50% formic acid in the sample loading buffer. However, 
we have noticed that analyzing ON hybridizations with high LNA content using denaturing 
PAGE does not always result in denaturation using standard protocols. For instance, due to 
the stronger binding of the LNA-ON to its target it might not necessarily give more 
information analyzing the interactions with denaturing PAGE compared to native PAGE. 
3.1.1 Electrophoretic mobility shift assay (EMSA) 
To determine the binding of bisLNA to plasmids containing the target sequence, EMSA was 
used as has been described previously for other and similar applications (283). BisLNA and 
plasmid were hybridized together at 37°C using intranuclear pH and salt concentrations (Tris-
acetate 50mM, [pH 7.4], 120mM KCl, 5mM NaCl, 0.5mM magnesium acetate) and treated 
with restriction enzymes for the generation of fragments of 150 bp consisting of bisLNA 
bound to the target sequence. The DNA fragments are then made visible using an 
intercalating dye (Ethidium Bromide or SybrGold) and analyzed using a gel documentation 
system with a camera. Depending on the chemical composition of the bisLNA, different 
constructs will bind to the target with different strength, and this was visualized and 
quantified using both PAGE and agarose gel electrophoresis. The plasmid linearization using 
the restriction enzymes relaxes the supercoiled DNA, which could result in detachment of the 
previously bound bisLNA. The ratio of bound bisLNA-bound target to the fraction of 
unbound target makes it possible to rank the compounds after binding efficacy. Since PAGE 
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after PAGE could be considered a strong binder. Agarose gels are used to compare and rank 
weaker binding bisLNAs, or to confirm findings obtained from the PAGE. 
3.1.2 Proximity EMSA 
As described for the bisLNA and EMSA in section 3.1.1, the EMSA was also used for 
assessing binding of the single stranded AGOs in paper II targeting the repeat regions in the 
HTT gene. Here, the same principle was used but the restriction enzymes were applied in a 
different way. Instead of generating fragments with restriction sites far from the target 
sequence, one restriction site was used located only one bp outside of the CAG repeats. When 
an AGO bind to the target, it will make it sterically more difficult for this restriction enzyme 
to cleave the DNA, which can be seen as a reduction in the fragment created from this site. 
Moreover, as AGOs with different lengths were tested, the longer AGO the higher the 
probability that a protruding unbound part of the AGO would interfere with this restriction 
enzyme, creating a length-dependent reduction in fragment intensity seen on the gel. See 
figure 7 below. This method has been used and described previously for PNA constructs and 
TFOs in assessing DNA binding (284, 285). 
 
Figure 7. Schematic picture of the proximity EMSA used to detect ON binding to a target plasmid. The presence 
of an ON hinders the cleavage by restriction enzymes giving rise to a characteristic restriction fragment pattern. 
3.2 S1 NUCLEASE ASSAY 
One way to visualize and quantify dsDNA strand invasion by AGOs is to take advantage of 
the S1 nuclease enzyme, which is capable of recognizing and cleaving single stranded regions 
within supercoiled DNA (286, 287). We have been using plasmids containing binding sites 
for our constructs to assess DSI capacity and allow for construct ranking. When DSI occurs 
by an AGO, short stretches of single stranded regions are formed around the binding sites for 
the construct (figure 8A). These are then cleaved by the S1 nuclease, creating a nicked or 
linear relaxed plasmid with a different migration rate during gel electrophoresis compared to 
the supercoiled plasmid. This allows us to calculate the amount of nicked/linear plasmid in 
relation to the remaining uncleaved plasmid and the corresponding ratio gives the percentage 
of DSI by one particular AGO. Since the plasmid always give some background nicking after 
S1 treatment due to plasmid dynamic DNA breathing, the overall percentage of DSI is 
normalized to the mock treated plasmid. 
  29 
 
Figure 8. A show the S1 nuclease assay and the single strand specific cleavage of unprotected regions in the 
invaded plasmid, and the resulting gel image. B show rolling circle amplification on the displaced strand 
following bisLNA binding. 
3.3 ROLLING CIRCLE AMPLIFICATION 
Rolling circle amplification (RCA) is a versatile technique for the detection of single 
molecules in complex biological environments. With such high sensitivity it has been used in 
many different settings (288-290), such as for the detection of DNA (291, 292), DNA 
methylation (293), small molecules (294, 295), single nucleotide polymorphisms (296), 
mRNA (297-299), antigens in immunoassays (300), viral RNA (301), and proteins (302). 
These applications clearly show how RCA can be performed in vitro, in bacteria, and in cells 
and tissues. 
The use of padlock probes (PLPs) in RCA (303, 304), where a hybridized targeting ON is 
circularized by ligation using the T4 ligase gives the technique the capacity to discriminate 
between single nucleotide mismatches (305). After the ligation, the circular PLP is amplified 
using primer extension creating a long, repetitive DNA sequence, which can be detected, by 
hybridization using small fluorescently labeled ONs. 
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In paper III RCA is used to show bisLNA binding to plasmids in solution and in bacteria. 
One challenge in this setting is the complexity of using hybridized DNA targets (see figure 
8B). The RCA uses phi29 DNA polymerase for the primer extension, which has varying 
efficiencies depending on the PLP-target complex. For instance, it has been shown that single 
stranded linear targets give more RCA product compared to circular targets, owing to the 
greater ability of phi29 to unwind a single stranded target during replication as the 5´ and 3´ 
ends are free (306). Thus, careful titration of the experimental conditions is needed for the 
detection of bisLNA binding. 
3.4 THERMAL UV-MELTING ASSAY 
The way in which an ON interacts with itself, its target sequence or other molecules such as 
proteins or specific ligands are important parameters to consider when designing or 
optimizing anti-gene or antisense strategies. The sequence composition, type of chemical 
modifications or synthetic nucleotides used together with the chemical environment will 
affect ON behavior both in vitro and in vivo (307). UV spectroscopy to follow the thermal 
denaturation of DNA and RNA with or without the presence of ligands can be a useful tool 
for the stability assessment of a complex. In this thesis UV melting, or temperature of melting 
(Tm), is used not only to characterize AGO target binding, but also for structural assessment 
of the constructs. Usually when investigating DNA and RNA duplexes, one would follow the 
change in absorbance at 260 nm as the temperature decreases or increases from a state of 
denaturation to renaturation. ssDNA or RNA absorbs more light at 260 nm than a duplex due 
to the unstacked state of the bases. Therefore, hyperchromicity is seen when a duplex is 
melted and reversely, hypochromicity is seen during renaturation of the duplex (308).  
To assess inter- or intramolecular structures, which could have important implications for ON 
efficacy, other wavelengths are often used to assess the Tm that better reflect the state 
transitions of interest. Complex structures such as a triplex or a G-quadruplex can be 
followed at 295 nm where they will show hypochromicity during the melting. It is often of 
interest to follow the melting curve at another wavelength in parallel for a better assessment 
of structure kinetics and behavior. Thus, for G-quadruplexes, 245 nm is often used in 
combination with 295 nm where the Tm and thermodynamic parameters should be the same 
for both wavelengths. Any deviations from these observations suggest more complex melting 
kinetics and imply a higher order of structural complexity (309). 
In paper IV the structural properties of a G-quadruplex forming aptamer and its related 
versions with different chemical compositions were characterized by UV melting at 295 and 
245 nm. These aptamers can adopt several conformations and show complex melting 
profiles. To further gain structural information that potentially could help understand the 
biological behavior of the aptamers, the Tm was also investigated in the presence of a G-
quadruplex ligand capable of stabilizing certain conformations. Since G-quadruplexes can 
form in the presence of both sodium and potassium ions, but not in the presence of lithium 
ions, all ONs used were dissolved in lithium cacodylate buffer and then adjusted to suitable 
concentrations of potassium or sodium. 
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There are several eneral factors that affect the Tm measurement to take into consideration 
(307, 309). First, the purity of the ON analyzed should be high. Secondly, the buffer used 
should not absorb light in the far UV region or have a pKa that is affected by temperature. 
Generally, cacodylate (pKa 6.14), acetate (pKa 4.62) or phosphate (pKa 6.81) buffers are 
acceptable for this purpose. Thirdly, the increase in temperature per minute could also affect 
the reading, since structures such as G-quadruplexes form and reform at slower rates than a 
duplex. This can lead to hysteresis effects when reformation of a structure during cooling 
occurs, with different kinetics than during melting. The effect will lead to a shift in the 
melting curve or overestimation of the Tm. Thus, a slow change in temperature is preferred 
(0.1 - 0.2 °C/min) when investigating complex structures. 
3.5 FOOTPRINTING 
To identify the exact binding location of an AGO in the target plasmid, DNA footprinting can 
be used. There are several footprinting methods developed to determine the specific binding 
of a ligand to its target along with its affinity and binding kinetics (310). The principle relies 
on the protecting properties of the ligand bound to DNA when subjected to chemical or 
enzymatic treatments. Unprotected areas where no ligand is present will be subjected to DNA 
modification and cleavage, whereas the sequence with bound ligand will withstand this 
treatment creating a chemical footprint at this position.  
The footprinting is visualized using radiolabeled or fluorescently tagged primers that are 
extended using the Sanger chain termination method (311), which will give rise to transcripts 
terminated at different positions. The sequence and the protected bases can be analyzed using 
dideoxy-nucleotides (ddNTPs) together with normal deoxy-nucleotides (dNTPs) during chain 
elongation.  ddNTPs, which lack the 3´-hydroxyl group, block further elongation of the chain 
when incorporated and this allows for the specific assessment of what is protected from the 
footprinting after sequencing and alignment of fragments. 
Classical footprinting is analyzed using denaturing gel electrophoresis and radiolabeled 
primers. In paper II footprinting with S1 nuclease and capillary electrophoresis detecting 
fluorescently labeled primers is used to assess binding of bisLNA compared to previously 
published results where the bisLNA was mapped using chloracetaldehyde treatment and 
radiolabeled primers (312).  
3.6 CELLULAR ASSAYS  
In this thesis, both AGO and aptamer effect and uptake are evaluated in cells. Culturing 
adherent cells in monolayer and using them in experimental settings such as those in the 
included papers require strict maintenance and awareness of important experimental 
parameters. To minimize irrelevant factors influencing the AGO evaluation, all cells used 
were tested for mycoplasma infection at regular intervals, and cells were grown in medium 
without any addition of antibiotics. Cells were split when reaching 90% confluency, and 
never used for more than 15 consecutive passages.  
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3.6.1 Transfections 
Using various transfection agents to deliver genetic material into cells are today standard 
methods in many laboratories. Many chemical reagents can be used and all have their own 
advantages and disadvantages (313). In this thesis lipofection, or positively charged lipid 
complexes, and cell penetrating peptides (CPPs) capable of forming nanoparticle complexes 
with the ONs are used to deliver the material into the cells. Both approaches involve an 
incubation phase in which the ONs are formulated together with the transfection reagent. The 
nanoparticle complexes are then given to the cells after which a period of incubation follows, 
usually several days, before the cells are analyzed. Factors affecting transfection efficiency 
include the ON and transfection agent concentrations, the formulation of ON-nanoparticle 
complex, the number of cells in the well, the type of cells transfected and the composition of 
the medium. These parameters should be optimized during the design of the experimental 
protocol, since suboptimal use will result in lower transfection efficiency at one extreme end 
and cellular toxicity at the other end.  
3.6.2 Gymnosis 
Gymnosis, or the unaided, naked delivery of ONs to cells (314), is a useful delivery method 
to investigate ON or aptamer uptake after entering cells through various receptor-mediated 
pathways. The internalization process efficacy will depend on ON sequence, chemistry and 
secondary structure, and after uptake the ON needs to escape endosomal entrapment before it 
can be released and locate to the cytoplasm or the nucleus of the cell. Typically, a 10 to 100-
fold higher concentration is needed for the ON to have effect after gymnotic delivery. 
However, as for transfections, delivery effect will also depend on factors such as ON 
concentration, total number of cells and cell type used. 
3.6.3 Cellular uptake studies 
The internal ON distribution as well as kinetic aspects of cellular uptake is a highly relevant 
experiment to perform. Depending on delivery method, chemistry and secondary structure, 
the ONs will show differences in cellular localization. This can be followed over time by 
using fluorescently labeled ONs, which can be imaged with a fluorescence microscope. Since 
AGOs are expected to have an effect on chromosomal DNA in the nucleus, ON accumulation 
in this compartment would be advantageous. However, the actual number of ONs needed to 
have an anti-gene effect may in some cases be lower than what can be detected with the 
fluorescence microscope, giving the false impression that no nuclear accumulation is present. 
Nuclear transporting could still be present where ONs could be transported from the 
cytoplasm to the nucleus in sufficient amounts to have an anti-gene effect. 
3.6.4 Cell viability assay 
As discussed above, cellular toxicity can be induced during the experimental conditions when 
studying ON effect and uptake. In certain cases, such as for the aptamer studied in paper IV, 
the expected effect after ON treatment is cytotoxicity which makes the elimination of non-
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specific toxic parameters by assay optimization highly important. To assess cell viability in a 
quantitative manner, the WST-1 assay was used in this thesis. This assay is similar to the 
MTT assay and relies on the change in absorbance when tetrazolium salts are cleaved by 
mitochondrial dehydrogenases to formazan. This conversion can be detected using a 
spectrophotometer and correlates to the number of metabolically active cells in the well. 
Normally, to reduce experimental variations, these reactions are carried out in 96-well plates 
using triplicates or quadruplicates. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
Fast and efficient synthesis of Zorro-LNA type 3'-5'-5'-3' oligonucleotide conjugates via 
parallel in situ stepwise conjugation 
Following the first publication describing the Zorro-LNA strategy for gene targeting and 
transcriptional blocking (83), the focus was on finding more efficient Zorro-LNAs by 
optimizing their chemical composition. One of the most effective Zorro-LNA constructs uses 
two ON DNA/LNA mixmer arms connected by a flexible HEG-linker (84). Unlike the first 
generation Zorro-LNA (Z-2ON), that uses a nucleotide linker through which the two arms 
can hybridize to each other, the HEG construct (Z-2HEG) is smaller in size but requires the 
arms to be connected in a 5´-5´ orientation. This in turn requires the use of reverse 
unmodified and LNA phosphoroamidites during synthesis in order to switch strand polarity in 
the sequence.  When many different compounds need to be generated for the screening of 
new targets, the use of reverse LNA amidites poses a problem, since they are not 
commercially available, therefore requiring in house synthesis of these building blocks.  
In paper I we developed a more simple screening procedure that could be used when 
designing new Zorro-LNA constructs taking advantage of the smaller size of the Z-2HEG 
and at the same time abolish the need for reverse amidites. This was achieved using Cu(I)-
mediated cycloaddition of a 5´-alkyne linked ON with a 5´-azide functionalized ON, a 
procedure called “click chemistry” used previously in related applications (315). Our “click 
chemistry” approach begins with the functionalization of two Zorro arms previously obtained 
commercially on a solid support. The arms are 5´-detritylated followed by the coupling of a 
5´-amino modifier (2-(N-(4-monomethoxytrityl)aminoethoxy)ethyl H-phosphonate) (98). In 
parallel, the amino linker containing the azido or triple bond is detritylated and activated 
followed by their addition to the Zorro arms on support. The functionalized arms are then 
deprotected and cleaved from the support and either clicked together directly in aqueous 
solution or kept separately as “free arms”, followed by HPLC purification.  
The new Zorro-LNAs and their corresponding “free arms” are shown in table 1 and figure 9 
and were compared to the old constructs Z-2ON and Z-2HEG in their double strand invasion 
(DSI) capacity. These constructs were previously designed to bind two adjacent target 
sequences in the plasmid pN25-2BS, and tested using 0 or 1 nt overlap between the two arms. 
Now, we investigated the influence of having 1 or 4 overlapping bases in the constructs. 
Finally, using the knowledge gained from the pN25-2BS construct comparison, we designed 
click Zorro-LNA against a novel target in the plasmid pN25-i5. Although we could see 
efficient DSI with the 2BS target, two identical adjacent target sites are rarely found in the 
genome. With the new “i5” target we were able to show, for the first time, DSI using two 
different Zorro-LNAs.  
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Name Sequence of Zorro arms Crude intermediate 
D1	 CCCtCCtcTTtcTTCa	 D1azido	
D4	
	
TgCcCCtCCtcTTTcTTCa	 D4azido	
U1	 GgCACccATgCgcTgA	 U1PATA	
U3	 cAacAaGcaCggCctC	 U3PATA	
D3	 TtgCcAgaCtcTgCc	 D3azido	
D2	 CccCagCcaCccTctG	 D2azido	
U2	 GgaAacCtcCctAaG	 U2PATA	
Table 1. Name and sequence of the Zorro arms and the modifications added for the preparation of 
“clickable” intermediates. D1 or D4 was combined with U1 for the 2BS target and D2+U2 and D3+U3 were 
combined for the new i5 target. Azido = 2-(2-(2-azidoethoxy) ethoxy) acetate acid, PATA = (N-
Propynoylamino)-p-toluic acid, LNA monomers in upper case, DNA in lower case. Reprinted from (95) with 
permission from the Royal Society of Chemistry. 
 
 
Figure 9. Zorro constructs used in the paper. Top panel shows the 2BS target sites in the plasmid beside the 
Zorro constructs compared along with their respective internal base overlap. Bottom panel shows the new i5 
target and the two different Zorro constructs used together with their internal base overlap. 
 
To compare the effect of having additional base overlap between the Zorro arms, the 
unmodified arms D1+U1 (1 nt overlap) and D4+U1 (4 nt overlap) were initially incubated 
together with the plasmid pN25-2BS at 37 °C using intranuclear salt conditions and pH for 
DSI assessment using the S1 nuclease assay. From these experiments we could see that the 4 
nt extended overlap did not reduce the DSI capacity. Interestingly, when the arms were 
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incubated separately together with the plasmid, we noticed that the D4 could invade the 
plasmid as efficiently as the D1+U1 together, while the D1 and U1 alone performed very 
poorly. This effect has been noted before, and could be due to a part of the D4 sequence 
acting as a TFO, thus enhancing the DSI performance compared to the other sequences (84). 
Next, we investigated the DSI of the clicked Zorros Z2BS-1 and Z2BS-4 and compared them 
to the previous constructs Z-2ON and Z-2HEG. Both click constructs showed time and dose 
dependent increase in DSI, but were not as efficient as the previous constructs, especially the 
Z-2HEG that showed almost double efficiency in comparison. We attributed these differences 
to the linker composition and the importance of using a flexible linker, such as the 2xHEG, 
when optimizing DSI for a lead Zorro construct after screening targets and sequences using 
the click chemistry approach. 
Finally, we wanted to investigate the ability to target two different adjacent sequences in a 
gene using our click Zorro constructs. Since we already showed that up to 4 nt overlap 
between the arms could be used, the new constructs Zi5-2 and Zi5-3 were designed using 2 
and 3 bases overlap respectively. These were then incubated with the pN25-i5 plasmid and 
we could demonstrate an increase in DSI over time using the tandem combination of Zi5-2 
and Zi5-3. Even though the overall DSI was lower for the i5 constructs compared to the 2BS, 
DSI using two different Zorro-LNAs were shown for the first time, which could potentially 
be utilized as a promising anti-gene strategy in the future using more optimized constructs. 
4.2 PAPER II 
GTC repeat-targeting oligonucleotides for down-regulating Huntingtin expression 
In paper II we developed modified ONs targeting the trinucleotide CAG repeat area in exon 1 
of the HTT gene, responsible for the disease phenotype seen in HD. Our therapeutic approach 
is based on the non-allele specific binding of LNA-containing ONs to chromosomal DNA, 
which will block transcription and production of both the wild type and mutant HTT protein 
thus reducing total HTT which in turn would reduce or possibly eliminate disease pathology 
and patient symptoms. At present, different treatment strategies are investigated by others 
(277, 282), and when ONs are used they normally are designed to target the mRNA to either 
block translation or induce degradation of the transcripts. Our aim of this paper was to a) 
show reduction in HTT levels in patient-derived fibroblasts and b) provide evidence that the 
effect comes after ON binding to DNA and not to RNA.  
First we designed CAG repeat DNA/LNA mixmer ONs with PS or PO backbone ranging in 
length from 10 up to 19 nts. These ONs were then tested in patient derived fibroblasts for the 
effect on HTT on both mRNA and protein levels using Q-PCR and Western Blotting. From 
these experiments it was shown that we could get stable and effective downregulation of 
mRNA and HTT levels, reaching as low as 35% remaining compared to untreated cells, at 
both 4 and 7 days after treatment. Moreover, we could show effect of the CAG-ONs at low 
nanomolar concentrations following transfection and low micromolar concentrations 
following gymnosis. The ONs with PS backbone all showed similar efficacy, while the PO 
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ONs did not give any effect on HTT levels following transfection. When following 
fluorescently labeled PS and PO CAG-ONs after transfection, we could detect high signal 
from the nucleus using PS ONs, while the PO ONs were mainly found in the cytoplasm. All 
ONs capable of downregulating HTT were able to do this regardless of ON length, with the 
exception of the 10-mers that were not effective at all, and the 12-mers that showed a reduced 
effect on mRNA after naked delivery. In addition, the 19-mer reduced the mutated HTT 
protein levels significantly more compared to the wild type HTT.  
We also designed two CAG ONs with the DNA bases exchanged for 2´-O-Me, or with four 
LNA bases exchanged for 2´-glycylamino 5-methylcytosine LNA. Their effect on HTT 
mRNA was assessed using both transfection and gymnosis. However, no improvement over 
the regular CAG-ONs was seen suggesting no added benefit using these kinds of 
modifications. 
To show that the CAG-ONs did not induce their effect by binding to HTT mRNA, we 
compared transcript levels after transfection with both CAG-ONs and CTG-ONs. The CTG-
ONs are antisense ONs complementary to the HTT mRNA and have been reported to inhibit 
translation by steric blocking (281). Indeed, only the CAG-ONs showed reduced mRNA 
levels, with the exception of a 19-mer CTG-ON, which gave a slight reduction of the mRNA 
as well. The HTT protein levels were highly reduced using both CTG and CAG ONs, 
confirming the steric antisense mechanism for the CTG-ONs and points to a different 
mechanism for the CAG-ONs consistent with DNA binding.  
To further study CAG-ON interactions with RNA we performed UV melting using CAG and 
CTG-ONs together with the RNA sequence (CAG). From these experiments it was evident 
that only the CTG-ON was able to give rise to a shift in Tm, while the CAG-ON did not. 
Thus, the CAG-ONs do not interact with the RNA, pointing to another mode of action in 
accordance with the observed results in cells. 
A more direct proof of CAG-ON binding to DNA was obtained using a plasmid containing a 
72 CAG repeat sequence. This plasmid was incubated together with the CAG-ONs, after 
which the restriction enzymes HindIII and AvrII were used to cleave near the ON binding 
site. HindIII cuts 40 bp 5´ upstream of the CAG sequence and 745 bp 3´of this region, while 
AvrII cuts just one bp outside. When analyzing the cleavage patterns using gel 
electrophoresis, it could be shown that AvrII had difficulties to cut the plasmid at this site. 
Moreover, the inhibition of cleavage was more pronounced using longer CAG-ONs, and this 
we interpreted as a steric blocking of the AvrII activity due to the presence of a CAG-ON. 
The longer CAG-ONs had a higher probability to interfere with AvrII cleavage, as seen by 
the weaker bands generated compared to the shorter CAG-ONs. 
These results together strongly suggests direct ON binding to the HTT DNA, even though a 
full understanding of the cellular effect is missing. HTT levels were clearly reduced without 
the ONs binding to mRNA. Along providing a possible new treatment strategy for HD, this 
AGO approach opens for new possibilities to treat diseases associated with repeat regions in 
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the gene. However, more studies are needed to closer evaluate the relationship between effect 
and DNA binding to exclude other possible mechanisms of HTT downregulation. Mainly, it 
has been suggested that ONs can have anti-gene effects by binding Antisense transcripts and 
affect gene expression by either sterically blocking or induce RNase H-mediated cleavage of 
the transcript (61). 
Indeed, for the HTT gene an Antisense transcript has been reported, spanning the region of 
exon 1 and 2 (316). It has been thought to be involved in the regulation of the sense 
transcript; consequently, any downregulation of this transcript would in fact increase the level 
of the sense HTT transcript. Thus, it is unlikely that our ONs act by binding to this Antisense 
transcript, further supporting our hypothesis that the effect comes from binding to 
chromosomal DNA and blocking of the polymerase during transcription. Future studies could 
provide detailed proof of this mode of action by searching for specific changes reflected on a 
chromatin level, as well as evidence of polymerase stalling. 
4.2.1 Preliminary results – Oligonucleotide chromosomal binding 
In order to confirm our CAG-ONs binding to chromosomal DNA we set out to investigate 
whether histone modifications are changed when cells are treated with the ONs. We reasoned 
that the silencing effect following ON treatment could be associated with reduced gene 
activation at the chromatin level. For instance, epigenetic silencing could be a plausible effect 
at certain locations in the HTT gene. The state of methylation and acetylation of the 
promoter-associated H3 are two modifications that correlate with the activation level of gene 
transcription. Thus, the H3 tri-methylation Me3 of K4 together with acetylation (Ac) of K27 
in this region is normally associated with active genes (317). As seen in figure 10, there was 
no loss of these markers, suggesting the ON effect to be independent from promoter 
activation and silencing.  
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Figure 10. Active histone marks are maintained across the HTT gene TSS during HTT mRNA 
knockdown. (A) UCSC genome browser image demonstrating RNA abundance H3K4me3 and H3K27ac 
abundance across the HTT gene TSS region. Primer positions used for ChIP-qPCR are numbered 1-7.  (B) 
H3K4me3 and (C)  H3K27ac abundance measured by ChIP-qPCR across the HTT TSS region. 
 
In addition, we also examined the ON effect on transcriptional elongation and RNA 
polymerase II serine 2 (S2) occupancy. Since the ON bind to exon 1 downstream of the 
polymerase initiation site, this might affect the elongation. The occupancy of S2 due to 
phosphorylation is correlated to gene expression and elongation rates, so that in 3´ exons of 
genes this occupancy will be higher compared to upstream (318). Any stalling of the 
polymerase in exon 1 due to ON blocking should therefore show lower occupancy at 
downstream exons while possibly have increased occupancy at or near exon 1, when 
comparing treated to untreated cells. As seen in figure 11, this is indeed the case, as the 3´ 
occupancy is reduced, and at the same time increased at exon 1 upstream of the CAG region, 
suggesting ON binding and stalling of polymerase elongation. 
1 Primer 2 3 4 5 6 7 
A 
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Figure 11. S2 phosphorylated RNA Pol II occupancy across the HTT gene is reduced upon transfection 
with HTT targeting ONs. (A) UCSC genome browser image demonstrating RNA Pol II S2 occupancy across 
the HTT gene. Primer positions at exon 1 upstream of the CAG repeat and at exons 30 and the last exon, 67, are 
indicated.  (B) RNA pol II occupancy is significantly increased at exon 1 of the HTT gene immediately upstream 
of the CAG repeat (*p<0.05) and reduced at the 3’ exons 30 and 67 (*p<0.05, ***p>0.001). (C) No difference is 
observed at control loci in the last exons of the PRDM1 or ACTB genes. 
 
 
Taken together these result clearly suggest the binding of the ONs to chromosomal DNA and 
that the effect on downregulation is indeed due to this binding. Further studies to show direct 
binding to chromosomal DNA using chromatin immunoprecipitation techniques or nascent 
RNA sequencing approaches could be performed in order to investigate this novel mode of 
action more thoroughly, especially to exclude the involvement of, or effect on, antisense 
transcripts spanning the region of binding. 
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4.3 PAPER III 
Next-generation bis-locked nucleic acids with stacking linker and 2'-glycylamino-LNA 
show enhanced DNA invasion into supercoiled duplexes 
This paper aims at investigating the influence of chemically modified nts and intercalators on 
DSI and DNA binding efficiency of different bisLNA constructs. It has previously been 
shown that the incorporation of LNA nts in the bis-LNA sequence has a positive effect on 
strand invasion, and that the binding is sequence-specific and using a linked clamp construct 
of two ONs for both WC- and HG-binding through a TFO is a feasible strategy (312). 
However, the mechanism of binding was not fully understood, as it was shown that using a 
single stranded ON binding via WC mode was as effective as the clamp construct, which also 
has the TFO arm. Thus, to fully take advantage of the different options for the enhancement 
of bisLNA constructs through chemically modified bases, a deeper understanding of the 
binding mechanism was needed.  
To investigate this, we examined how both the WC and TFO arms contribute to strand 
invasion by incubating them together with a target plasmid, separately and in combination. 
Here we could see that the free TFO makes it harder for the WC arm to strand invade. At the 
same time, reducing the number of LNAs in the TFO arm makes strand invasion less 
efficient, possibly due to a higher kinetic rate of dissociation of the TFO. These findings led 
to the proposed mechanism of binding where the bisLNA first binds to the target sequence by 
forming a triplex involving its TFO. After this, DSI most probably begins from the tail of the 
WC arm. This is supported by several experimental observations such as tail containing 
bisLNAs are more efficient compared to clamp-only containing constructs, and the reduction 
of bases in the tail region, or mutations in the corresponding target sequence, reduce the 
invasion efficiency severely. 
Intercalating molecules introduced in the bisLNA constructs were shown to affect the 
stabilization of the WC and HG arms after hybridization to the target DNA. The TINA 
intercalator gave very different results on the compound performance depending on the 
position where it was placed. BisLNAs carrying a TINA in the TFO part could stabilize the 
triplex formation, however, when placed in the WC arm at the junction, the final complex is 
destabilized even though overall strand invasion was improved.  
One important finding we made was that the linker region connecting the TFO arm with the 
WC arm has a major influence on strand invasion efficiency of the bisLNA. By replacing the 
5 nt DNA linker with an intercalating moiety called M3 (319), strand invasion was much 
improved as shown using both S1 nuclease assay and EMSA. This positive contribution to 
efficacy was attributed to the stacking properties and optimal length of the M3 linker due to 
increased initial triplex formation and enhanced cooperative effect between both arms. These 
observations were further highlighted by the fact that taking away the TFO arm diminished 
the advantages of having an M3 in the linker, and this effect was even more pronounced 
when using a scrambled TFO arm. M3 stacking and stability enhancement seems to require a 
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proper triplex formed. M3 linkers are of particular interest in bisLNA clamp constructs, 
which do not rely on any WC tail at all, since such constructs devoid of an intercalator 
showed very low DSI capacity.  
We could also demonstrate that M3 molecules are beneficial for TFO stabilization not only in 
the linker region. When placed in the 5´ extrimity as well as in the linker for the clamp 
constructs, strand invasion was even higher.  By testing strand invasion in plasmids 
containing mutated target sequences we could show that the specificity of M3 containing 
constructs was maintained, as the discriminatory ability of the TFO part of the bisLNA was 
much higher with the M3 constructs compared to the ones without, again stressing the 
accuracy of our mechanistic explanation that binding starts with the TFO formation.  
Since the triplex is destabilized by the electrostatic repulsion of the phosphate backbone of 
the three strands, we sought to investigate if introducing LNA analogues carrying a positive 
charge into the constructs could reduce this repulsion. Indeed, both the 2´-aminoglycyl LNA 
modified clamp and tail bisLNAs showed great improvements in strand invasion, possibly 
due to an advantageous conformation favoring interactions between the positive charge and 
the phosphate group, reducing the overall electrostatic repulsion. When combined with M3 
intercalating moieties, very efficient bisLNA constructs were demonstrated with high strand 
invasion capacity at low concentrations (< 500 nM). 
The need for efficient and stable TFO formation for bisLNA constructs was further 
demonstrated when targeting different genomic locations. Here we found that strand invasion 
efficiency in plasmids was heavily influenced by the target sequence base composition. C-
rich bisLNA constructs were found to be less efficient which is probably due to the need for 
C protonation in the TFO contexts, something that is not efficient at physiological pH. 
Finally we wanted to test the bisLNA performance in a more complex context. E.coli bacteria 
containing target plasmids were grown on microscope slides after which the bisLNA was 
incubated with the bacteria on the slides and strand invasion assessed using RCA. We found 
that without bisLNA, very low rolling circle product and signal was detected, indicating 
bisLNA binding on target since high signal was detected in the bacteria where the bisLNA 
was present. We also concluded that RCA could not be induced from other bacterial 
components since bacteria containing control plasmid and bisLNA gave very little signal. 
Taken together, we have successfully constructed very efficient and novel bisLNAs with high 
strand invasion capacity at low concentrations. We also present substantial evidence to the 
mechanistic model of bisLNA binding, starting at the TFO, and the constructs were applied in 
a biological context were they showed target specific binding and efficacy.  
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4.4 PAPER IV 
Delivery, effect on cell viability, and plasticity of modified aptamer constructs  
In paper IV we investigated the effect on cellular uptake and conformational plasticity of a set 
of aptamer-connected ONs. Aptamers are ONs capable of adopting secondary structures that 
are recognized by ligands, such as cell surface receptors that could enable specific uptake. 
The aptamer we have studied is called AS1411 and was developed some ten years ago as a 
potential treatment for tumors that overexpress the NCL receptor on the cell surface (208). 
AS1411 can adopt a G4 conformation and can bind and become internalized through NCL 
receptors in targeted cells, where it reduces viability. We wanted to use the targeting and 
internalization process to study the potential of the aptamer to deliver LNA containing cargo 
ONs into the cells. These ONs were previously tested elsewhere individually or combined as 
Zorro arms, and one of these (named Tox) was found to be highly cytotoxic. To test the 
combined aptamer + ON, they were synthesized as one chimeric construct and delivered to 
cells using both lipofection and by gymnotic delivery. We also wanted to investigate the use 
of UNA in the loop regions for the G4-forming aptamer sequence, which could potentially 
change the aptamer folding properties. 
First we set out to confirm that the chimeric constructs maintained the cytotoxic effect seen 
using Tox alone and in combination with the second ON, noTox. This was shown by 
transfecting the constructs into A549 and U2OS cells at low nanomolar concentrations and 
assessing cell viability after 24h using the WST-1 assay. Since we were able to confirm the 
effect of Tox in all constructs and combinations, we concluded that there was no negative 
influence on efficacy of using Tox in a chimeric context.  
Secondly, we wanted to investigate the effect on cell viability under gymnotic conditions. 
During 5 days, the constructs were incubated at 37 °C with A549 cells, and cell viability was 
determined again using the WST-1 assay. From these experiments we found that only the 
aptamer alone and the chimeric aptamer-Tox construct had an effect on cell viability at low 
micromolar concentrations. One construct, which carried the noTox hybridized to the 5´ end 
of aptamer-Tox, showed reduced toxicity. UNA substitutions in the loop region of the G4- 
forming aptamer did not influence the effect of AS1411 alone, but slightly reduced the effect 
in the chimeric construct connected to Tox.  
The fact that the inherent toxicity of AS1411 alone a) disappeared when attached to noTox, 
b) was reduced when connected to a large cargo (Tox+noTox) and c) was reduced in the 
UNA chimeric construct, led us to suspect that the cargo ON by size or chemical composition 
could affect the conformational plasticity of the aptamer needed for effective binding and 
internalization. Thus we looked at the cellular uptake of AS1411 and the chimeric constructs 
in A549 cells by using fluorescently labeled ONs. Here it was evident that only the AS1411 
and AS1411-Tox was internalized efficiently since very low signal was detected from the 
AS1411-noTox.  
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On the other hand, when the constructs were tested in U2OS cells, we noticed that only the 
cargo-less AS1411 with UNA substitution had any effect on cell viability after naked 
delivery. The overall effect on cell viability using this construct was also much reduced 
compared to A549 cells, and when following uptake in U2OS cells we could see that the 
signal was indeed very low. This led us to conclude that the aptamer does not enter U2OS as 
efficiently as A549 cells, possibly due to different number of expressed NCL receptors on the 
cell surface. 
Since it was evident from the cell experiments that the cargo ON could affect the 
internalization properties of the chimeric constructs, we wanted to compare the folding and 
conformational profiles using UV-melting and gel shift electrophoresis. Since the AS1411 is 
known to adopt G4 conformations, we followed their melting profiles at 295 nm in the 
presence of KCl. Indeed the Tm transitions in all constructs were indicative of the presence of 
G4 structures, but no differences indicated by changes in Tm and folding kinetics were 
observed for the AS1411 constructs. Neither were any structural differences seen using gel 
electrophoresis. However, the UNA based chimeric constructs showed hysteresis effects 
during reformation of the G4, suggesting differences in folding kinetics. This was also 
reflected in the cellular experiments as these constructs showed reduced effect. The AS1411 
alone did not suffer from hysteresis effects during UV melting, which was consistent with the 
higher effect seen in cells compared to the chimeric UNA constructs. From this we concluded 
that UNA substitutions in the loop region are acceptable in the aptamer alone, but give a 
negative contribution to the chimeric construct plasticity and cellular effect. 
It has been previously reported that the AS1411 can adopt several G4 conformations, and it 
has been problematic to try to characterize these conformations using various techniques. 
Furthermore it is not known which conformation is biologically relevant. This led us to 
investigate a novel approach to characterize conformational changes in the AS1411 by using 
small molecule G4 ligands as probes. G4-binding molecules capable of stabilizing G4 
structures have been used extensively in the literature for various purposes. Here we 
synthesized two novel ellepticine derivatives called 1-ChE and 1-OxE for the purpose of 
following their stabilizing effect on the conformations of the aptamer constructs during UV 
melting to assess any subtle differences not otherwise possible to detect. 
From these experiments we could see a dose dependent stabilization of the G4 structure of 
AS1411 indicated by an increase in Tm for each fold of molar excess of the G4 ligand 
present. The 1-ChE was more effective compared to 1-OxE indicated by higher Tm shifts, 
however, no significant difference in the melting profiles was observed compared to the 
chimeric constructs. In contrast, when comparing the UNA containing aptamer alone to the 
corresponding chimeric construct carrying Tox, a dramatic hysteresis effect was observed in 
the presence of G4 ligand. This correlates well with the observed reduced effect of this 
construct in cells, suggesting a conformational difference of this construct.  
Taken together, we showed that AS1411 could efficiently deliver toxic LNA ONs to cells. 
However, we provided evidence of the importance of aptamer cargo composition and the 
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effect it can have on plasticity of the construct and cellular uptake. These parameters need to 
be taken into consideration when designing future chimeric constructs for the specific 
delivery of cargo to targeted cells.  
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5 CONCLUDING REMARKS 
This thesis describes different applications of gene targeting ONs and the use of aptamers for 
the specific delivery of ON cargo into cells. A useful screening strategy for Zorro-LNA 
optimization using click chemistry is presented, as well as investigations on ON effect 
following DNA binding or double strand invasion. Single stranded ONs targeting the HTT 
gene have been shown to downregulate HTT expression, and their binding to DNA and not 
RNA was demonstrated on several levels. BisLNAs were developed using various 
chemistries, and we could show that the most efficient constructs for strand invasion needed a 
stacking linker and aminoglycyl LNA, in combination with a stable TFO. 
When using aptamer mediated delivery of ON cargo into cells, the chemical compostion of 
the ON is important since it can have a direct effect on cellular uptake. The structural 
plasticity of the chimeric constructs need to be carefully characterized, especially when 
incorporating modified bases such as UNA, which did not automatically correlate with 
greater activity. 
Given the recent advances and success seen with ASO therapeutics, the future holds great 
promise also when it comes to AGO approaches. Still, several hurdles need to be overcome 
for this to become a reality. As for all ON therapeutics, the delivery is still the main issue for 
targeting disease tissues. So far, the most successful treatments have been locally 
administrated since systemically administered ONs mainly end up in either the liver or 
kidneys due to their pharmacokinetic properties, even when formulated with delivery 
vehicles.  
On the other hand, ONs can have great effect in these organs, illustrated by the many 
therapeutics under investigation equipped with the GalNAc functional group for enhanced 
uptake in the liver. Thus, for CNS-active ONs, such as those used for investigative HD 
treatments, local administration to the brain through intracerebroventricular injections or 
related techniques seems likely to be the route of choice, since the blood brain barrier is not 
permeable for this class of therapeutics. Indeed, ON effect and exposure after single 
injections of therapeutic doses seem to be present several weeks in the brain (276).   
To show DNA binding in a chromosomal context is the ultimate proof of the AGO concept. 
Our preliminary result on serine 2 phosphorylation on RNA polymerase II suggests ON 
binding to the DNA and the subsequent stalling of transcriptional elongation. Future 
experiments can give further insights to the complex assessment of such mechanisms. These 
would likely benefit from the use of many different assays in combination for a greater 
understanding of the basic principles associated with gene transcription during ON-binding. 
This thesis provides a starting point for such investigations, and hopefully these small steps 
could some day move the anti-gene field closer to treatments and benefits for the patient. 
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